BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 1349527)

  • 1. Polyclonal immunoglobulin therapy protects against cardiac damage in experimental coxsackievirus-induced myocarditis.
    Weller AH; Hall M; Huber SA
    Eur Heart J; 1992 Jan; 13(1):115-9. PubMed ID: 1349527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CTLA4-Ig relieves inflammation in murine models of coxsackievirus B3-induced myocarditis.
    Han B; Jiang H; Liu Z; Zhang Y; Zhao L; Lu K; Xi J
    Can J Cardiol; 2012; 28(2):239-44. PubMed ID: 22336520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a murine model of myocarditis induced by a reactivated coxsackievirus B3.
    Zhang H; Yousef GE; Ouyang X; Archard LC
    Int J Exp Pathol; 1994 Apr; 75(2):99-110. PubMed ID: 8199011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decay-accelerating factor (CD55) promotes CD1d expression and Vgamma4+ T-cell activation in coxsackievirus B3-induced myocarditis.
    Huber S; Song WC; Sartini D
    Viral Immunol; 2006; 19(2):156-66. PubMed ID: 16817758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coxsackievirus-induced myocarditis is dependent on distinct immunopathogenic responses in different strains of mice.
    Huber SA
    Lab Invest; 1997 May; 76(5):691-701. PubMed ID: 9166288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Demonstration of suppressor cells in coxsackievirus group B, type 3 infected female Balb/c mice which prevent myocarditis.
    Job LP; Lyden DC; Huber SA
    Cell Immunol; 1986 Mar; 98(1):104-13. PubMed ID: 3017580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T lymphocyte responses in CVB3-induced murine myocarditis.
    Huber S; Polgar J; Moraska A; Cunningham M; Schwimmbeck P; Schultheiss P
    Scand J Infect Dis Suppl; 1993; 88():67-78. PubMed ID: 7685923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCL10 inhibits viral replication through recruitment of natural killer cells in coxsackievirus B3-induced myocarditis.
    Yuan J; Liu Z; Lim T; Zhang H; He J; Walker E; Shier C; Wang Y; Su Y; Sall A; McManus B; Yang D
    Circ Res; 2009 Mar; 104(5):628-38. PubMed ID: 19168435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased susceptibility of male BALB/c mice to coxsackievirus B3-induced myocarditis: role for CD1d.
    Huber SA
    Med Microbiol Immunol; 2005 May; 194(3):121-7. PubMed ID: 15107990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vgamma4(+) T cells promote autoimmune CD8(+) cytolytic T-lymphocyte activation in coxsackievirus B3-induced myocarditis in mice: role for CD4(+) Th1 cells.
    Huber SA; Sartini D; Exley M
    J Virol; 2002 Nov; 76(21):10785-90. PubMed ID: 12368321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of coxsackievirus B3 myocarditis in mice by lobenzarit disodium through inhibition of splenic pan T cells.
    Kishimoto C; Takada H; Kuroki Y; Matsushita I; Hiraoka Y; Kurokawa M; Ochiai H; Sasayama S
    Cardiovasc Res; 1993 Feb; 27(2):243-8. PubMed ID: 8386064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coxsackievirus B3 induction of NFAT: requirement for myocarditis susceptibility.
    Huber SA; Rincon M
    Virology; 2008 Nov; 381(2):155-60. PubMed ID: 18829062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coxsackievirus-induced disease. CD4+ cells initiate both myocarditis and pancreatitis in DBA/2 mice.
    Blay R; Simpson K; Leslie K; Huber S
    Am J Pathol; 1989 Nov; 135(5):899-907. PubMed ID: 2573284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coxsackievirus B3 induces T regulatory cells, which inhibit cardiomyopathy in tumor necrosis factor-alpha transgenic mice.
    Huber SA; Feldman AM; Sartini D
    Circ Res; 2006 Nov; 99(10):1109-16. PubMed ID: 17038643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T cells expressing the gamma delta T-cell receptor potentiate coxsackievirus B3-induced myocarditis.
    Huber SA; Moraska A; Choate M
    J Virol; 1992 Nov; 66(11):6541-6. PubMed ID: 1328680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coxsackievirus B-3 myocarditis. Acute and chronic forms of the disease caused by different immunopathogenic mechanisms.
    Lodge PA; Herzum M; Olszewski J; Huber SA
    Am J Pathol; 1987 Sep; 128(3):455-63. PubMed ID: 2957924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The mechanisms responsible for the therapeutic effects of anti-Fas ligand antibody on viral myocarditis in mice].
    Chang H; Han B; Han XZ
    Zhonghua Er Ke Za Zhi; 2005 Dec; 43(12):920-4. PubMed ID: 16412356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AIM2 Co-immunization with VP1 Is Associated with Increased Memory CD8 T Cells and Mounts Long Lasting Protection against Coxsackievirus B3 Challenge.
    Yin L; Chai D; Yue Y; Dong C; Xiong S
    Front Cell Infect Microbiol; 2017; 7():247. PubMed ID: 28642849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zinc finger antiviral protein inhibits coxsackievirus B3 virus replication and protects against viral myocarditis.
    Li M; Yan K; Wei L; Yang J; Lu C; Xiong F; Zheng C; Xu W
    Antiviral Res; 2015 Nov; 123():50-61. PubMed ID: 26343012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of protective immune responses against coxsackievirus B3 challenge by DNA prime-protein boost vaccination.
    Lan J; Gao Z; Xiong H; Chuai X; Jin Y; Li J; Xian X; Liu G; Xie L; Zhang Y; Wang Y
    Vaccine; 2011 Sep; 29(40):6894-902. PubMed ID: 21803097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.